What investors actually look for in your traction story

Vanity metrics get you a second meeting, not a term sheet

Total sign-ups, app downloads, waitlist size and press mentions are screening metrics at best. They tell an investor you can generate attention. They do not tell an investor whether attention converts into a durable business, and healthcare investors have been burned enough times by digital health hype cycles that they now discount these numbers on sight.

What replaces them in a serious diligence process is a small set of numbers that show the shape of your funnel over time: activation rate, time to first value, net revenue retention, and the ratio of expansion revenue to new logo revenue. A HealthTech company with modest top-line growth but 130 percent net revenue retention is a more fundable story than one with explosive sign-ups and no retention data.

The traction story investors actually diligence

Growth equity and Series A investors in healthcare will ask for a cohort table before they ask for your total addressable market slide. They want to see, month by month, how a cohort of customers or pilot sites behaves after month one: does usage grow, plateau or decay. Decay with a plausible fix is fundable. Decay with a shrug is not.

They will also ask how much of your pipeline is founder-sourced versus repeatable. A pipeline built entirely on the founder's personal network is a red flag at Series A, even if it produced strong logos, because it does not scale past the founder's calendar. Investors want to see the first signs of a motion that does not require the CEO on every call.

• Cohort retention and usage trend, not just logo count
• Sales cycle length trending down as your ICP narrows, not widening
• Pipeline sourced by channel: founder network versus repeatable motion
• Gross margin and cost to serve, especially for anything touching clinical workflow or services
• Reference customers willing to take an unscripted investor call

Qualitative diligence: the calls you cannot script

Every serious HealthTech investor will ask to speak to two or three of your customers directly, without you on the call. What they are listening for is whether the customer describes the same problem and the same value you described in your deck, in their own words, and whether they would be upset if the product disappeared tomorrow.

Founders who prepare for this by curating a warm reference list of friendly early adopters usually get caught, because investors ask the same three questions across every diligence process and compare notes with other funds in the syndicate. The stronger move is to let the investor pick from a list of six to eight references, including at least one that churned or almost churned, and to be candid about why.